Literature DB >> 7860210

Cytomegalovirus infections in renal transplant patients.

X G Zhang1, M K Chan.   

Abstract

The incidence of cytomegalovirus infection in Chinese patients was reviewed in a retrospective study of 99 renal transplant recipients. CMV infection occurred in 18 patients (18.2%). In 4 the infection was considered primary and in 14 it was thought to be reactivation. Of the infections 88.9% occurred within the first 6 months after transplantation, 44.4% were asymptomatic, while the rest had protean manifestations with the commonest combinations of fever, hepatic dysfunction and haematological abnormalities. One patient succumbed to the infection. Significant difference was seen in the incidence of CMV infections among patients who had received different antirejection therapy, being the highest (37%) among those who had received either Atgam or OKT3. Among the various secretions, urine gave the best yield of virus cultures.

Entities:  

Mesh:

Year:  1994        PMID: 7860210     DOI: 10.1007/bf02767664

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  31 in total

1.  Use of intravenous immunoglobulin prophylaxis for primary cytomegalovirus infection post living-related-donor renal transplantation.

Authors:  D R Steinmuller; D Graneto; C Swift; A C Novick; S B Streem; R J Cunningham; E Hodge; P Bretan
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

2.  Effect of 9-(2-hydroxy-1-[hydroxymethyl] ethoxymethyl) guanine (DHPG) on cytomegalovirus pneumonitis after renal transplantation.

Authors:  M Stoffel; P Gianello; J P Squifflet; Y Pirson; G P Alexandre
Journal:  Transplantation       Date:  1988-10       Impact factor: 4.939

3.  Treatment of cytomegalovirus infections in renal transplant recipients with 9-(1,3-dihydroxy-2-propoxymethyl) guanine.

Authors:  M Cantarovich; C Hiesse; O Lantz; S Fassi-Fihri; B Charpentier; D Fries
Journal:  Transplantation       Date:  1988-06       Impact factor: 4.939

4.  The clinical application of a rapid diagnostic test for the detection of cytomegalovirus infection in renal transplant recipients.

Authors:  S F Lui; P Sweny; J E Grundy; A Blaxill; P D Griffiths; J F Moorhead; O N Fernando
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

5.  Foscarnet for cytomegalovirus infections.

Authors:  O Ringdén; H Wilczek; B Lönnqvist; G Gahrton; B Wahren; J O Lernestedt
Journal:  Lancet       Date:  1985-06-29       Impact factor: 79.321

6.  Effect of treatment with cyclosporine versus azathioprine on incidence and severity of cytomegalovirus infection posttransplantation.

Authors:  M J Bia; W Andiman; K Gaudio; A Kliger; N Siegel; D Smith; W Flye
Journal:  Transplantation       Date:  1985-12       Impact factor: 4.939

7.  Acute renal failure induced by foscarnet: 4 cases.

Authors:  P Cacoub; G Deray; A Baumelou; P Le Hoang; W Rozenbaum; M Gentilini; C Soubrie; R Rousselie; C Jacobs
Journal:  Clin Nephrol       Date:  1988-06       Impact factor: 0.975

Review 8.  Cytomegalovirus infections following renal transplantation.

Authors:  J Glenn
Journal:  Rev Infect Dis       Date:  1981 Nov-Dec

9.  Complications and monitoring of OKT3 therapy.

Authors:  J R Thistlethwaite; J K Stuart; J T Mayes; A O Gaber; S Woodle; M R Buckingham; F P Stuart
Journal:  Am J Kidney Dis       Date:  1988-02       Impact factor: 8.860

10.  Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients.

Authors:  G Klintmalm; B Lönnqvist; B Oberg; G Gahrton; J O Lernestedt; G Lundgren; O Ringdén; K H Robert; B Wahren; C G Groth
Journal:  Scand J Infect Dis       Date:  1985
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.